SOPHIA ANTIPOLIS, France – March 7, 2025 │ A few days ago, Regeneron decided to no longer seek accelerated approval of odronextamab, a bispecific antibody (bsAb) CD20 x CD3, for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, the company is continuing to pursue this approval for follicular lymphoma (FL), with an FDA[…]
SOPHIA ANTIPOLIS, France – February 04, 2025 │ Advancements in oncology have consistently pushed the boundaries of therapeutic innovation, particularly in the realm of immunotherapy. BioNTech’s BNT327, a bispecific antibody targeting vascular endothelial growth factor (VEGF) and Programmed death-ligand 1 (PD-L1), represents a cutting-edge approach to treating difficult cancers such as triple-negative breast cancer (TNBC).[…]
SOPHIA ANTIPOLIS, France – February 04, 2025 │ KnowMade actively tracks therapeutic mRNA innovations as part of its Therapeutic mRNA patent monitoring services. What’s new today? CHMP Recommends Approval of KOSTAIVE® (ARCT-154) EMA opinion The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval[…]
SOPHIA ANTIPOLIS, France – January 30, 2025 │ The last quarterly report for the 2024 Therapeutic mRNA patent monitor is now available! As we leave behind another year, we look back on the mRNA therapeutic patenting activity! The year 2024 marked another dynamic period for technological innovation in mRNA therapeutic area, the race for intellectual[…]